- Research category
- GLP-1 / Weight Management
- Format
- Lyophilized peptide material
- Purity spec
- Greater than 99%
- Availability
- Approved accounts
- Documentation
- COA coming soon
Certificate of Analysis coming soon
GLP-1 / Weight Management
Semaglutide
Single GLP-1 receptor agonist with extensive clinical-data familiarity. The compendium notes the same active compound as Ozempic and Wegovy and describes approximately 15% body-weight reduction in clinical trials. Mechanism: GLP-1 receptor activation reduces appetite, slows gastric emptying, and stimulates insulin.
- Availability
- Wholesale Access Only
Semaglutide · Research use only
Research context
Weight management; protocols/patients with existing semaglutide familiarity.
Material information
- Grade
- Research Use Only (RUO)
- Format
- Lyophilized peptide material
- Purity
- Greater than 99%
- Appearance
- Lyophilized powder
Documentation
Batch-specific documentation may be available for approved account review. View documentation standards.
Regulatory status
For laboratory research use only. Not for human consumption, diagnosis, treatment, cure, or prevention of disease.
Restrictions
Research use only
This material is offered for research use only. Not for human or animal use. Not intended for clinical, diagnostic, therapeutic, veterinary, or personal use. PeptaPharma does not provide dosing, administration, or treatment guidance.
Related materials
Synthesized & tested in the United States.
PeptaPharma materials are produced and analytically tested in U.S. facilities. Batch-level documentation and Certificates of Analysis accompany each lot for approved-account review.